If you are using mobile devices, please swipe to the right to view the full content

FRIDAY, 4 NOVEMBER 2022

TIME TRACK 1 TRACK 2 TRACK 3
8.00 9.30 Registration
  Miscellaneous Head & Neck SBRT Workshop
9.30 9.50 Updates on NET- Oncology perspective
David Tai, National Cancer Centre Singapore
(Virtual)
Artificial intelligence in head and neck cancers: Is this the future?
Ajay Aggarwal, University College London
(Virtual)
Introduction to SBRT: History, rationale and basic radiobiology
9.50 10.10 Nuclear Medicine approach in the management of NET; the present and the future
Zool Hilmi bin Awang, Thompson Hospital Kota Damansara
HPV positive oropharyngeal cancers: What is the best approach?
Nahjatul Kursiah, Hospital Likas
Clinical data for SBRT Lung: Efficacy and toxicity data, comparisons with other treatment
10.10 10.20 Q&A Q&A Q&A
10.20 10.55 Opening Ceremony 
10.55 11.05 Tea Break Tea Break Tea Break
11.05 11.25 Cancer of Unknown Primary - the challenges, and treatment strategies
Fuad bin Ismail, Universiti Kebangsaan Malaysia
Radiotherapy for head and neck cancer post reconstructive surgery
Imjai Chitapanarux, Chiang Mai University
Discussion of dose-fractionation schemes and tolerance doses for oragans at risk
11.25 11.45 Ewing Sarcoma - First line therapy and beyond
Teh Kok Hoi, Hospital Tunku Azizah
Managing toxicities with advanced radiotherapy techniques in head and neck cancer
Ho Kean Fatt, Mt Miriam Hospital
Follow up considerations: Imaging, toxicity management
11.45 12.05 Melanoma : New insights and new therapies
Abel Zachariah, Pantai Hospital Ayer Keroh
Reirradiation in Head and Neck cancer - How safe is safe?
Melvin Chua, National Cancer Centre Singapore (Virtual)
Practical considerations for an SBRT programme
12.05 12.25 Requirements for optimal surgery in sarcoma
Zulmi Wan, Prince Court Medical Centre
Role of EBV testing and adjuvant treatment in NPC
Nur Fadhlina Abdul Satar, University Malaya
OAR and target delineation - discussion using ProKnow
12.25 12.45 Proton therapy in Paediatric Cancers
Kanjana Shotelersuk, King Chulalongkorn Memorial Hospital
Updates on systemic therapy of relapsed/metastatic head and neck cancer
Wan Zamaniah Wan Ishak, University Malaya
12.45 13.00 Q&A Q&A Q&A
1.00 2.00 Lunch symposium 1a Lunch symposium 1b Lunch symposium 1c
  Urology Central Nervous System SBRT Workshop
2.00 2.20 New advances in metastatic bladder cancer
Senthil J. Rajappa, Basavatarakam Indo American Cancer Hospital & Research Institute
Glioma: Updates on classification and molecular profiles
Wong Kum Thong
Rationale for Spine SBRT - the WHY
2.20 2.40 Adjuvant therapy in renal cell carcinoma
Ravindran Kanesvaran, National Cancer Centre Singapore
Case-based discussion: Low and high grade glioma
Presenter: Zulaikha binti Rozman, University Malaya
Yong Chen Joyce, University Malaya
Neurosurgeon: N. Vairavan, University Malaya
Oncologist: Biswa Mohan Biswal, KPJ Ipoh Specialist Centre
Technical Intricacies in the delivery of spine SBRT - the HOW
2.40 3.00 Sexual health in prostate cancer 
Ong Teng Aik, University Malaya
3.00 3.10 Q&A Q&A Q&A
3.10 3.55 Tea Symposium 1a Tea Symposium 1b Tea Symposium 1c
3.55 4.15 RARP vs SBRT for prostate cancer
Surgeon: Warren Lo Hwa Loon, Hospital Kuala Lumpur
Oncologist: Ibrahim Wahid, Beacon Hospital
Case-based discussion: Multiple brain metastases
Presenter: Asyraf Muaadz bin Abd Kudus, University Malaya
Neurosurgeon: Hari Chandran, University Malaya
Oncologist: Doris Chow, Pantai Hospital Penang
Views through a clear lens - the WHAT and WHERE - Imaging in spinal metastases
4.15 4.35 PROKNOW contour review of selected cases
4.35 4.45 Q&A Q&A Q&A
7.00 10.00 Conference Dinner (by invitation only)

SATURDAY, 5 NOVEMBER 2022

TIME TRACK 1 TRACK 2 TRACK 3
8.30 9.00 Registration
  Lung Breast Research
9.00 9.20 Optimal biomarker testing in lung cancer 
Pathmanathan Rajadurai, Subang Jaya Medical Centre
Understanding high recurrence risks in early breast cancer
Nur Fa'izah, Universiti Kebangsaan Malaysia
Establishment of Asian Cancer Trial Network: ATLAS
Nakamura Kenichi, Japan Clinical Oncology Group
9.20 9.40 Perioperative therapy in NSCLC
Arnil Sirimanne, Prince Court Medical Centre
Chemotherapy in early breast cancer. What has changed?
Najihah Abu Bakar, National Cancer Institute
Multi-omics for cancer precision medicine: from bench to bedside
Paul Townsend, University of Surrey
9.40 10.00 Adjuvant therapy in Stage 1 NSCLC
Adlinda Alip, University Malaya
Immunotherapy in early breast cancer
Natasha Mohd Hashim, KPJ Johor Specialist Centre
Next Level Collaboration: Sarawak-ASCO collaboration in the midst of pandemic
Sharon Choo Yoke Ling, Sarawak General Hospital
10.00 10.15 Q&A Q&A Q&A
10.15 11.00


Industry Sponsored: Pfizer


Industry Sponsored: Zuellig Pharma


Industry Sponsored: AstraZeneca

      Allied Health
11.00 11.20 Treatment paradigm in resectable EGFR mutation positive NSCLC
Muhammad Azrif, Prince Court Medical Centre
Optimizing adjuvant and neoadjuvant therapy for HER2 positive breast cancer
Kiley Loh, Penang Adventist Hospital
Role of nurses in oncology emergencies 
Nor Aziyan binti Yahaya, University Malaya
11.20 11.40 Locally advanced lung cancer: A multidisciplinary team approach
Presenter: Daniel Gan
Surgeon: Narasimman.S
Oncologist: Soo Hoo Hwoei Fen
The role of adjuvant CDK4/6 inhibitors in HR+ HER2- early breast cancer
Lim Yueh Ni, Sarawak General Hospital
Care of intravenous therapy devices in oncology
Azizan binti Mohd Isa
11.40 12.00 Making sense of PARP inhibition in early breast cancer
Voon Pei Jye, Sarawak General Hospital
Nursing challenges in cancer patients 
Rosnani binti Sarkasi, International Islamic University Malaysia
12.00 12.20 Low Her2 advanced breast cancer: The dilemma
John Low
Spiritual needs of cancer patients: Challenges for nurses
Rosnida binti Abu Bakar, Open University Malaysia
12.20 12.40 Treatment approach in uncommon EGFR mutations in NSCLC
Azura Rozila Ahmad, Beacon Hospital
HR+ HER2- metastatic breast cancer: beyond CDK4/6 inhibitors
Vaishnavi Jeyasingam, Hospital Kuala Lumpur
Specialized home care nursing: Are you ready?
Azrimah Binti Zainudin, National Cancer Institute
12.40 1.00 Q&A Q&A Q&A
1.00 2.00


Industry Sponsored: Astra Zeneca


Industry Sponsored: Novartis


Industry Sponsored: MSD

2.00 2.20 Addressing resistance to immune checkpoint inhibitors
David Lee, University Malaya
Case-based discussion : Challenge your experts
Presenter
ER Positive- Ooi Po Lin
HER2 Positive- Jonathan Chew Chia Wei
TNBC- Anbarasan A/L Anbazagan
Panelist
Ho Gwo Fuang, University Malaya
Kiley Loh, Penang Adventist Hospital
Vaishnavi Jeyasingam, Hospital Kuala Lumpur
EBRT dose calculation algorithm: the past, present and future
Shaun Baggarley, National University Hospital Singapore
2.20 2.40 Uncommon mutations in NSCLC
Heng Fook Yew, Sarawak General Hospital
2.40 3.00 Maximising therapy for non-oncogene addicted NSCLC
Matin Mellor, Subang Jaya Medical Centre
Physicists' perspective: Setting up an SBRT programme
Shaun Baggarley, National University Hospital Singapore
3.00 3.10 Q&A Q&A Q&A
3.10 3.55


Industry Sponsored: Merck


Industry Sponsored: Ipsen


Industry Sponsored: Roche

3.55 4.15 Neoadjuvant treatment in SCLC
Shahzril Imran, Pantai Hospital Sungai Petani
Beyond immunotherapy in metastatic TNBC
Ho Gwo Fuang, University Malaya
XVI dual registration tool for image-guided radiotherapy
Mohd Khairul bin Mohd Zambri, Columbia Asia Hospital
4.15 4.35 The current treatment paradigm of Mesothelioma
Anna Lim, National Cancer Institute
Recent advances in HER2 positive advanced breast cancer
Mastura Md Yusof, Pantai Hospital Kuala Lumpur
4DCT challenges: From the lens of a radiation therapist
Nur Idalia bt Abd Majid, KPJ Ampang Puteri Specialist Hospital
4.35 4.45 Q&A Q&A Q&A
5.00 7.00 Annual General Meeting (MOS members only)

SUNDAY, 6 NOVEMBER 2022

TIME TRACK 1 TRACK 2 TRACK 3
8.30 9.00 Registration
  Gastro Intestinal Brachytherapy Nutrition
9.00 9.20 HCC - Novel agents beyond 1st line therapy
Tan Chih Kiang, Thompson Hospital Kota Damansara
Brachytherapy for tongue carcinoma
Umesh Mahantshetty, Tata Memorial Hospital, India
Nutrition therapy team in cancer treatment: Fact or fiction?
Ratha Krishnan Sriram, Queen Elizabeth Hospital Kota Kinabalu
9.20 9.40 New updates in biliary tract malignancies
Harissa Husainy Hasbullah, Universiti Teknologi Mara
Brachytherapy vs SBRT liver
Gokula Kumar, Universiti Sains Malaysia
Updates on latest guidelines in clinical nutrition for cancer patients
Luqman Mazlan, Pantai Hospital Kuala Lumpur
9.40 10.00 Locally advanced pancreatic cancer: To palliate or to cure?
Audi Adawiyah Sulaiman Shah, Hospital Wanita Kanak- Kanak Sabah
CT-based contouring in IGBT for cervical cancer
Umesh Mahantshetty, Tata Memorial Hospital, India
Improving gut tolerance during chemotherapy
Norshariza Jamhuri, National Cancer Institute
10.00 10.15 Q&A Q&A Q&A
10.15 11.00 Breakfast Symposium 3a Breakfast Symposium 3b Breakfast Symposium 3c
    Gynaecology
11.00 11.20 Surgery in localised gastric and GOJ cancer
Lim Shyang Yee
Penang Adventist Hospital
Cervical cancer screening in Malaysia: Removing Obstacles to Cervical Screening (ROSE)
Yogeeta Gunasegaran, University Malaya
Enhancing nutrition support in difficult enteral access
Tee Sze Chee, National Cancer Institute
11.20 11.40 Current therapy standard for early stage gastric & GOJ cancers
Hadi bin Abd Jalil, Sarawak General Hospital
Advances in immunotherapy for cervical cancer
David SP Tan, National University of Singapore
Inadequate calories or protein- Why aren't they responding to therapy?
Hans Alexander Mahendran, Hospital Sultanah Aminah
11.40 12.00 Immunotherapy in gastric and GOJ cancer - Still a long way to go?
Eng Jie Yi, Sarawak General Hospital
Review of adjuvant treatment in endometrial cancer
Ibtisam Mohd Noor, Hospital Kuala Lumpur
The role of microbiota during cancer therapy; Friend or foe
Hazreen Abd Majid, University Malaya
12.00 12.20 Metastatic HER2+ gastric cancer - recent updates
Norhidayu Bt Salimin, National Cancer Institute
Molecular classification in endometrial cancer: Impact on clinical practice
Cheah Soon Keat, Island Hospital
Immunonutrition: The new silver bullet?
Mohammad Shukri Jahit, National Cancer Institute
12.20 12.40 Immunotherapy in advanced oesophageal cancer
Patricia Shamani, National Cancer Institute
Platinum sensitive ovarian cancer: Therapy updates
Nur Adila Mokhtar, University Malaya
Refeeding syndrome the silent killer
Lau Peng Choon, Pantai Hospital Kuala Lumpur
12.40 1.00 Q&A Q&A Q&A
1.00 2.00 Lunch Symposium 3a Lunch Symposium 3b Lunch Symposium 3c
      Fertility
2.00 2.20 New updates in advanced pancreatic cancer
Nellie Cheah Lay Chin, Loh Guan Lye Specialists Centre
Free paper presentation Fertility boost for male cancer patients
Muhilan Parameswaran,Thomson Hospital Kota Damansara
2.20 2.40 Total neoadjuvant treatment in rectal cancer - Fact or myth?
Nik Muhd Aslan, Sunway Medical Centre
Improving chance for pregnancy in female cancer patients
Wai Kok Yau, Thomson Hospital Kota Damansara
2.40 3.00 Avoidance of surgery after a pCR in rectal cancer
Nur Afdzillah Abdul Rahman, Universiti Kebangsan Malaysia
Fertility sparing surgery in gynaecological cancer
Badrul Zaman, Regency Specialist Hospital
3.00 3.15 Q&A Q&A Q&A
3.15 3.45 Closing Ceremony

DISCLAIMER: Whilst every attempt would be made to ensure all aspects of the conference mentioned in the Programme will take place as scheduled, the Organising Committee assumes no responsibility should it fail to materialize due to any unforeseen circumstances.

VIEW PROGRAMME IN PDF